Sonnet BioTherapeutics, Inc. (NASDAQ:SONN)

BRIEF

published on 03/11/2024 at 12:35, 8 months 11 days ago

Sonnet BioTherapeutics Moves Toward Phase 2 in Clinical Trial for Neuropathy Treatment

Sonnet BioTherapeutics SON-080 Phase 1b/2a Clinical Trial Chemotherapy-Induced Peripheral Neuropathy Diabetic Peripheral Neuropathy
PRESS RELEASE

published on 03/11/2024 at 12:30, 8 months 11 days ago

Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Sonnet BioTherapeutics successfully completes Phase 1b trial of SON-080 with positive safety profile, paving the way for Phase 2 trial in Diabetic Peripheral Neuropathy (DPN) after potential partnership

Sonnet BioTherapeutics SON-080 Diabetic Peripheral Neuropathy Phase 1b Trial DSMB
BRIEF

published on 02/29/2024 at 22:10, 8 months 22 days ago

Sonnet BioTherapeutics Reports a Safe and Tolerable Phase I Trial for SON-1010 in Healthy Volunteers

Cancer Research Immunotherapy Sonnet BioTherapeutics SON-1010 Phase I Trial
PRESS RELEASE

published on 02/29/2024 at 22:05, 8 months 22 days ago

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Sonnet BioTherapeutics Holdings, Inc. announced the publication of clinical data on SON-1010, a tumor-targeted immunotherapeutic drug combining FHAB construct with IL-12 in Frontiers in Immunology, showing favorable safety and tolerability

Clinical Data Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug FHAB Technology
PRESS RELEASE

published on 02/14/2024 at 13:30, 9 months 8 days ago

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Sonnet BioTherapeutics Holdings, Inc. successfully raised $4.55 million, published preclinical data on SON-1210, executed NJ NOLs agreement, Phase 1b SON-080 trial enrollment completed, financial results announced for quarter ended Dec 31, 2023

Financial Results Preclinical Data Public Offering Sonnet BioTherapeutics Holdings NJ NOLs
PRESS RELEASE

published on 12/21/2023 at 14:00, 11 months 1 day ago

Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
PRESS RELEASE

published on 12/14/2023 at 22:15, 11 months 8 days ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
PRESS RELEASE

published on 10/31/2023 at 12:30, 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
PRESS RELEASE

published on 10/25/2023 at 13:30, 1 year ago

Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
PRESS RELEASE

published on 10/17/2023 at 14:00, 1 year 1 month ago

Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Published on 11/22/2024 at 23:55, 9 hours 19 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 44 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 10 hours 9 minutes ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 10 hours 9 minutes ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 44 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 14 hours 59 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 15 hours 13 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 15 hours 20 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 18 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 17 hours 13 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 18 hours 38 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 2 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 13 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News